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Abstract
Background: The development of chemoresistance and metastasis are the leading causes of death for gastric
cancer (GC) patients, however, the molecular mechanisms involved remain unclear. Dysregulation of miRNAs is
associated with a variety of disease, including GC. Recently, microarray profiling analysis revealed that miR-939 was
dysregulated in human GC samples, but the role of miR-939 in GC has not been intensively investigated.
Methods: In the present study, we firstly examined the expression pattern of miR-939 in two independent cohorts of
clinical GC samples: one cohort of 112 GC patients with stage I-III disease who underwent surgery followed by adjuvant
chemotherapy; and another cohort of 110 GC patients with stage IV disease who received palliative chemotherapy.
A series of in vivo and in vitro assays were then performed to investigate the function of miR-939 in GC.
Results: We detected that reduced expression of miR-939 was associated with chemoresistance and increased risk of
tumor recurrence in GC patients. Further function study demonstrated that overexpression of miR-939 suppressed GC
cell growth, and enhanced 5-fluorouracil-induced chemosensitivity by compromising cellular growth and inducing
apoptosis in vitro and in vivo. Moreover, miR-939 repressed the migration and invasion of GC cells in vitro, and
diminished the occurrence of lung metastasis in vivo. We further identified solute carrier family 34 member 2
(SLC34A2) was a novel target of miR-939. Mechanistically, we elucidated that miR-939 exerted its function mainly
through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC. Multivariate analysis identified miR-939,
SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients.
Conclusion: Our data indicate that miR-939 acts as a tumor suppressor miRNA in GC, and miR-939/SLC34A2 axis
represents a novel therapeutic strategy for future GC treatment.
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Background
Gastric cancer (GC) is one of the most common causes
of cancer-related deaths worldwide [1]. At present, sur-
gical resection and palliative chemotherapy are the back-
bone treatment modalities for early staged and advanced
staged GC patients, respectively [2]. Although tremen-
dous progress has been made in therapeutic strategies,
the prognosis for GC patients using existing treatments
remains unsatisfactory. The development of chemoresis-
tance and metastasis are the leading causes of death for
GC patients, however, the molecular mechanisms in-
volved remain unclear [3–5]. Therefore, a better under-
standing of these molecular events will undoubtedly
facilitate our ability to the development of novel thera-
peutic targets and strategies for GC treatment.
MicroRNAs (miRNAs) are a class of small-regulatory
RNA molecules that repress protein translation through
binding to the 3’-untranlated region (UTR) of their tar-
get mRNA [6]. Aberrant expression of miRNAs has been
reported in various types of cancers [7, 8]. In GC, miR-
192, miR-215, miR-25 are reported to be upregulated,
whereas miR-375, miR-101 are downregulated [9–12].
Nevertheless, the role of miRNAs in the regulation of
GC-associated genes, and thus the role of miRNAs in
the pathogenesis of GC, remains elusive.
Recently, microarray profiling analysis revealed that a
number of miRNAs were dysregulated in human GC
samples compared with normal tissues, including miR-
939 [13]. However, the clinical significance and
biological role of miR-939 in GC is still not known.
Therefore, we devised our present study to find out the
mechanism of miR-939 action and its potential clinical
application in GC. Interestingly, we found that decreased
miR-939 expression is closely related with poor clinical
outcome of GC patients. Our data showed that miR-939
inhibits GC metastasis and enhances the sensitivity of
GC cells to 5-fluorouracil (5-Fu) treatment. In addition,
we identified that miR-939 exerts its tumor-suppressing




Gastric cancer cell lines (AGS, BGC-823, HGC-27,
MGC-803, MNK-45, and SGC-7901), and one immortal-
ized human gastric epithelial mucosa cell line (GES-1)
were grown in DMEM medium supplemented with 10%
fetal bovine serum.
Samples and patients
For the use of clinical materials for research purposes,
prior approval was obtained form the Committees for
Ethical Review of Research at Sun Yat-Sen University
(Guangzhou, China). Formalin-fixed paraffin-embedded
(FFPE) tumorous and adjacent non-tumorous tissues
samples from 112 GC patients, who underwent surgical
resection between January 2010 and December 2011,
were randomly selected from the archives of the Depart-
ment of Pathology of Sun Yat-Sen University Cancer
Center (Guangzhou, China). All the patients enrolled
were diagnosed with stage I-III GC disease during sur-
gery resection, and received postoperative adjuvant 5-
Fu-based chemotherapy: SOX regimen (Tegafur plus
oxaliplatin), XELOX regimen (capecitabine plus oxalipla-
tin), Tegafur, or capecitabine. The clinicopathological
characteristics of the patients in this cohort are summa-
rized in Additional file 1: Table S1. The patients were
followed every 3 months for the first year and then every
6 months for the next 2 years, and finally annually,
thereafter. The diagnostic examinations consisted of CT,
MRI, abdominal ultrasonography and bone scan when
necessary to detect recurrence and/or metastasis. During
follow-up period, 48 patients experienced tumor recur-
rence or metastasis, and 38 deaths due to cancer-related
diseases.
In addition, we obtained another independent cohort
of 110 patients, who were diagnosed with stage IV GC
disease between January 2008 and December 2013. The
mean age at diagnosis was 56 years (range, 21–81 years);
72 patients were male. The patients in this cohort were
administrated with fluorouracil-based regimen (SOX or
XELOX) as first-line palliative chemotherapy. The re-
sponse of chemotherapy was assessed based on CT
examination every 6 weeks during therapy and at the
end of treatment according to the following criteria:
complete response (CR) as defined by the complete reso-
lution of all assessable lesions; partial response (PR) as
defined by a reduction by 50% or more of the sum of
the lesions and no progression of assessable lesions; or
no change (NC) as indicated by a reduction <50% or in-
crease <25% in tumor size. The CR, PR or NC condi-
tions had to last for at least 4 weeks without appearance
of new lesions. Otherwise the response will be counted
as progressive disease (PD) as defined by an increase of
25% in tumor size or appearance of new lesions.
The clinical and clinicopathological classification and
stage were determined according to the American Joint
Committee on Cancer (AJCC) criteria. Patients who had
a single primary lesion without neoadjuvant therapy be-
fore operation were included in the study. Other criteria
for inclusion were as follows: age >18 years; histologi-
cally confirmed gastric cancer with at least one measur-
able lesion as defined by the Response Evaluation
Criteria in Solid Tumors; Eastern Cooperative Oncology
Group performance status (ECOG PS) of B2, and life ex-
pectancy >3 months.
For both XELOX and SOX regimen, oxaliplatin
(130 mg/m2) was diluted in 500 mL of 5% dextrose and
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infused intravenously over 2 h on day 1. Oral adminis-
tration of capecitabine (1000 mg/m2) and Tegafur (body
surface area, BSA < 1.25: 40 mg; BSA 1.25–1.5: 50 mg;
BSA > 1.5: 60 mg) was followed twice a day from days 2
to 15 in XELOX and SOX regimen, respectively. Treat-
ment was continued until 6–8 cycles of XELOX, SOX,
Tegafur, or capecitabine had been completed, disease
progression, unacceptable toxicity, patient withdrawal,
or physician’s decision.
RNA isolation and quantitative real-time PCR
Total RNA was extracted from cultured cells and tissue
specimens using TRIzol (Invitrogen, Calsbad, CA). Real-
time PCR was carried out with SYBR Green SuperMix
(Roche, Basel, Switzerland) using ABI7900HT Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
U6 was used as an internal control. An optimal cutoff
value for “high” or “low” miR-939 expression was identi-
fied based on the median value of the cohorts of patients
tested. TaqMan probes were used to detect miR-939,
SLC34A2, U6, and GAPDH (GeneCopoeia, Guangzhou,
China).
MTT assay
Cell viability was measured by a 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay
(Sigma, St, Louis, Missouri, USA). Briefly, cells were
seeded in 96-well plates and treated with various con-
centration of 5-Fu for each well. The absorbance was
measured at 570 nm, with 655 nm as the reference
wavelength. All experiments were carried out in
triplicates.
Colony formation assay
Cells were placed in six-well plate (500 cells/plate) and
cultured for 2 weeks. Colonies were fixed with methanol
for 5 min, and stained with 0.1% crystal violet for 30 s.
Flow cytometric analysis of apoptosis
Annexin V-APC and propidium iodide (PI) stains were
carried out to assess the percentage of cells undergoing
apoptosis. The apoptosis assay was conducted using the
protocol supplied by the manufacturer (BioVision Inc.).
Each sample was then subjected to analyses by flow cy-
tometry (Beckman Coulter, cytomics FC 500, CA).
Wound-healing, migration and invasion assays
For cell would-healing assay, the movement of cells was
measured in a scraped, acellular area made by a 200 ml
pipette tube, and the spread of wound closure was ob-
served after 24 h. For migration assay, 40,000 cells were
added to the upper chamber in serum free media and
migration at 37 °C towards 10% FBS containing growth
media was determined either after 24 h. Cells migrated
through the membrane were fixed, stained and counted
under light microscope. For invasion assays, 1 × 105 cells
were seeded into a Matrigel invasion chamber (BD Bio-
sciences, NJ, USA) in a 24-well culture plate. After 24 h,
the invasive cells located on the lower side of the cham-
ber were fixed in methanal, stained with crystal violet,
and followed by counting under a light microscope.
Western blot (WB) assay
Equal amounts of cell protein lysates were resolved by
SDS-polyacrylamidegel electrophoresis (PAGE) and elec-
trotransferred on a polyvinylidene difluoride (PVDF)
membrane (Pall Corp., Port Washington, NY) according
to standard methods. The following primary antibodies
were used: anti-SLC34A2 (Abcam, Cambridge, UK); anti-
GAPDH, anti-AKT, anti-p-AKT, anti-ERK, anti-p-ERK,
anti-c-Raf (Cell signaling Technology, Beverly, MA).
Immunohistochemical (IHC) Staining
In brief, tissue sections were de-waxed and incubated in
retrieval buffer solution for antigen recovery. We used
the Dako Real Envision Kit (K5007, Dako) to visualize
protein expression after staining with primary antibody.
Staining intensity was scored manually by two independ-
ent experienced pathologists as 0 = no staining, 1 = weak
staining, 2 = moderate staining, and 3 = strong staining.
Tumor cells in five fields were randomly selected and
scored based on the percentage of positively stained cells
(0–100%). The final IHC score was calculated by multi-
plying the intensity score with the percentage of positive
cells (range from 0 to 3). An optimal cutoff value was
identified based on the median value of the cohorts of
patients test.
Vector construction and retroviral infection
The miR-939 expression vector (HmiR0533-MR03), the
control vector for miR-939 (CmiR0001-MR03), the coding
sequences of SLC34A2 expression vector (EX-A3175-
Lv105), and the control vector for SLC34A2 (EX-NEG-
Lv105) were purchased from the GeneCopoeia Company
(Guangzhou, China). Cells transfected with empty vector
were used as controls. The vectors were packaged using
the ViraPower Mix (Genecopoeia, Guangzhou, China) in
293FTcells. After culturing for 48 h, the lentiviral particles
in the supernatant were harvested and filtered by centrifu-
gation at 500 g for 10 min, and then transfected into the
GC cells.
Mimic, antagomir, plasmids and transient transfection
miR-939 mimic and antagomir-939 were purchased from
GeneCopoeia Company (GuangZhou, China). Oligo-
nucleotide transfection was performed with Lipofectamine
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2000 reagent (Invitrogen, Carlsbad, CA), according to the
manufacturer’s instructions.
Luciferase reporter assay
The 3′ UTR of SLC34A2 were amplified and cloned
downstream to the luciferase gene in a modified pGL3
control vector. The firefly luciferase construct was
cotransfected with a control Renilla luciferase vector
into GC cells in the presence of miR-939 mimic,
antagomir-939, or miR-control. A dual luciferase assay
(Promega) was performed 48 h after transfection. The
experiments were performed independently in triplicate.
Animal experiments
For in vivo metastasis assays,six Four-week-old BALB/c
nude mice in each experimental group were injected
with SGC-7901/control or SGC-7901/miR-939 cells, re-
spectively. Briefly, 2 × 105 GC cells in 30 μl of 33%
Matrigel (Becton Dickinson, NJ, USA) were injected
intravenously through the tail vein. The experiment was
terminated 28 days after tumor-cell inoculation, and
metastatic nodules in each lung were counted.
For xenograft growth of orthotopic animal model
assay, the mice were randomly divided into four
groups (n = 6): SGC-7901/control, SGC-7901/miR-939,
SGC-7901/control + 5-Fu, SGC-7901/miR-939 + 5-Fu,
and equal amounts of SGC-7901/miR-939 or SGC-
7901/control cells (3 × 106) were injected subcutane-
souly into the flank of each mouse. For chemotherapy
treatment group: 5-Fu was administered at a dose of
5 mg/kg at 10 am twice a week for 3 week; for con-
trol groups, DMSO alone (100% DMSO, 40 lL, intra-
peritoneal injection every 2 days) was delivered to the
mice. Treatment began on day 7, when the tumors
were measurable. The tumors were examined twice
weekly, length and width measurements were ob-
tained with calipers, and the tumor volumes were cal-
culated. On day 25, the animals were euthanized and
the tumors were excised and weighed.
All the procedures were carried out in accordance
with the guidelines of the Laboratory Animal Ethics
Committee of Sun Yat-Sen University.
Statistical analysis
Statistical analysis was performed using a SPSS software
package (SPSS Standard version 16.0, SPSS Inc). Re-
ceiver operating characteristic (ROC) curve analysis was
conducted to evaluate the predictive value of miR-939
expression in predicting GC chemotherapy response.
Comparisons between groups for statistical significance
were performed with a 2-tailed Student’s t test. Bivariate
correlations between study variables were calculated by
Pearson’s correlation coefficients. Differences between
variables were assessed by the Chi-square test or Fisher’s
exact test. For survival analysis, we analyzed all GC pa-
tients by Kaplane-Meier analysis. A log rank test was
used to compare different survival curves. Multivariate
survival analysis was performed on all parameters that
were found to be significant in univariate analysis using
the Cox regression model. P values <0.05 were consid-
ered significant.
Results
Expression of miR-939 is downregulated in GC and closely
related to clinical outcomes
To explore miR-939 expression in GC, we conducted
real-time PCR assay. As shown in Fig. 1a, b, the expres-
sion of miR-939 was significantly decreased in human
GC cell lines and human primary GC tissues compared
with normal gastric epithelial cell lines and nontumor
human gastric tissues, respectively (P < 0.05).
Next, we analyzed miR-939 expression using pretreat-
ment tissue specimens from 112 GC patients with stage
I-III disease who underwent surgery resection followed
by adjuvant chemotherapy. We detected that miR-939
levels were significantly decreased in patients who
showed local relapse or distant metastasis in comparison
to patients who did not have tumor relapse or metastasis
during our follow-up period (P < 0.05,Fig. 1c).
To further determine the clinical implication of miR-
939 expression, we conducted qRT-PCR assay in 110
pretreatment samples from stage IV GC patients who
received palliative chemotherapy. Among the enrolled
cases, there were 0, 57, 36, and 17 patients satisfied the
criteria for complete response (CR), partial response
(PR), no change (NC) and progressive disease (PD) at
the evaluation time, respectively. We observed that miR-
939 showed a negative correlation with chemotherapy re-
sponse in our enrolled cases, in which low expression of
miR-939 was observed more frequently in NC + PD subset
(41/56, 73.2%) than in CR + PR set (15/56, 26.8%) (P <
0.001, Table 1). Moreover, Receiver operating characteris-
tic (ROC) curves analysis demonstrated that a promising
predictive value of miR-939 regarding GC chemotherapy
response (area under the curve [AUC] =0.777, P < 0.001,
Fig. 1d).
miR-939 inhibits the GC growth in vitro and in vivo
Next, we investigated the effects of miR-939 on GC by
overexpressing or inhibiting miR-939 in GC cell lines.
MTT and colony formation assays revealed that overex-
pression of miR-939 significantly increased the growth
rate of both GC cell lines; conversely, depletion of miR-
939 promoted GC cell proliferation and tumorigenicity
in vitro (Fig. 1e, f ). Next, we sought to determine
whether miR-939 sensitized GC cells to 5-Fu treatment,
the common used chemotherapeutic drug in GC pa-
tients. As shown in Fig. 2a, b, the combination of 5-Fu
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with miR-939 was more efficient in reducing the GC cell
viability and the clone formation ability. We further ex-
amined whether miR-939 increased the sensitivity of GC
cells to 5-Fu by enhancing the rate of apoptosis. The
AnnexinV-PI assay showed that miR-939-overexpressing
cells displayed increased cellular apoptosis and necrosis
in response to 5-Fu treatment at 48 h (Fig. 2c). More-
over, a significant increase in level of cleaved caspase-3
and PARP I in miR-939-overexpressing cells treated with
5-Fu was detected by western blot analysis (Fig. 2d).
Fig. 1 miR-939 is down-regulated in gastric cancer tissues and cell lines, and inhibits GC proliferation. a comparison miR-939 expression in six GC
cell lines and non-transformed epithelial cell line, GES-1. b comparing differences in the expression levels of miR-939 between tumor and corresponding
non-tumor tissues. c comparing differences in the expression levels of miR-939 between GC tumor tissues from recurrent and non-recurrent patients. d
the predictive value of miR-939 expression regarding the chemotherapy response in 110 patients with advanced GC disease. ROC curve analysis for miR-
939 expression was performed to assess GC treatment response (area under the curve [AUC] = 0.777, P < 0.001). e and f MTT assays (e)
and colony formation assay (f) indicate that the proliferation and tumorigenicity of miR-939-overexpressing cells was decreased, and that
of the miR-939-silenced cells was increased, compared with control cells. Expression levels of miR-939 were determined by qRT-PCR and
normalized against an endogenous control (U6 RNA). *P < 0.05, ** P < 0.01
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Together, these results demonstrate that miR-939 pro-
moted the apoptosis of GC cells.
We also demonstrated miR-939’s ability to inhibit the
GC growth using GC orthotropic animal model in vivo.
As shown in Fig. 2e, we found that overexpression of
miR-939 could significantly compromise GC tumor
growth in vivo, and moreover, the combination of miR-
939 and 5-Fu showed more significant inhibition of
tumor growth, compared to either miR-939 or 5-Fu
alone. Similarly in Fig. 2f, g, the group receiving combin-
ation of miR-939 and 5-Fu had lower average tumor
weight and volume, compared with the groups receiving
miR-939 or 5-Fu alone. More importantly, the combin-
ation of miR-939 and 5-Fu is well tolerated by the test
animals in vivo, as indicated by mouse body weight
(Fig. 2h). Thus, results suggested that miR-939 could en-
hance the sensitivity of GC cells to chemotherapies in
vivo.
miR-939 inhibits GC cell metastasis in vitro and in vivo
As lower expression of miR-939 was observed in pa-
tients with distant metastasis in GC, and distant metas-
tasis often resulted in resistance to the conventional
chemotherapy drugs, we sought to determine whether
miR-939 has inhibition on GC metastasis. We confirmed
that overexpression of miR-939 suppressed cellular mi-
gration and invasion, whereas miR-939 inhibition pro-
moted migration and invasion in vitro (Fig. 3a-c).
Moreover, we stained the cancer cells that spread into
lung of mice. Number and size of the metastatic
colonization were dramatically decreased on the lung
surface of miR-939-transfected cells implanted mice
compared to the control mice, and the miR-939 overex-
pression group exhibited much lower Ki-67 IHC staining
of tumor metastases than the control group (Fig. 3d).
miR-939 enhances GC chemosensitivity and inhibits
metastasis by directly targeting SLC34A2
Using miRNA target prediction algorithms, we identified
solute carrier family 34 member 2 (SLC34A2) as tenta-
tive target of miR-939 (Fig. 4a). The luciferase reporter
assay indicated that overexpression of miR-939 signifi-
cantly repressed the luciferase activity of SLC34A2-
3’UTR, while inhibition of miR-939 increased the
luciferase activity of SLC34A2-3’UTR. Meanwhile, ec-
topically expressing miR-939 mutation had no inhibitory
effect on the SLC34A2-3’UTR luciferase activity (Fig. 4b).
As shown in Fig. 4c, d, the expression levels of SLC34A2
mRNA and protein were significantly decreased follow-
ing the ectopic expression of miR-939; In contrast, the
inhibition of miR-939 led to an increase in the expres-
sion of SLC34A2 at both the mRNA and protein level.
Consistently, overexpressing miR-939 mutation had no
comprising effect on SLC34A2 mRNA and protein ex-
pression level (Fig. 4c, d). Moreover, our clinical data
show that the expression levels of miR-939 and
SLC34A2 were negatively correlated in 112 GC samples
(r = −0.623, P < 0.001, Fig. 4e, f ).
To determine whether SLC34A2 directly contribute to
miR-939 function, SLC34A2 was overexpressed in miR-
939-overexpressing GC cells (Fig. 5a). As expected,
restoration of SLC34A2 can block the miR-939-
enhanced chemosensitivity and induction of apoptosis
by 5-Fu treatment (Fig. 5b-d). Also, exogenously
expressed SLC34A2 compromised the inhibition of me-
tastasis by miR-939 on GC cells (Fig. 5e-f ). Taken
together, these data suggest that SLC34A2 played an im-
portant role for the effects of miR-939 on GC cells.
miR-939 attenuates ERK1/2 phosphorylation and inhibits
the Raf-MEK-ERK pathway
Previous studies have documented that PI3K/AKT and
MAPK/ERK signaling pathway play crucial roles in de-
velopment of chemoresistance and metastatic ability in
human malignancies [14–16], thus we investigated the
roles of miR-939 in the activation of PI3K/AKT and
MAPK/ERK pathway. We found that the expression
level of P-ERK was significantly decreased in cells with
stable overexpression of miR-939 (Fig. 5g, lane 1, 2).
This effect was reversed when we restored the SLC34A2
expression (Fig. 5g, lane 3). And pretreatment with
ERK inhibitor U0126 could obviously reduce the ex-
pression level of P-ERK (Fig. 5g, lane 4). However,
the P-AKT and AKT levels were not significantly al-
tered. The observation that miR-939 compromised
ERK1/2 activation leads us to further investigate the
effect of miR-939 overexpression on RAS-RAF-MEK-
ERK pathway. We found obvious inhibition of RAF-
MEK-ERK pathway upon miR-939 overexpression,
whereas restoration of SLC34A2 attenuated this com-
promising effect (Fig. 5h).
Clinical significance and prognostic values of miR-939 and
SLC34A2 in GC patients
We evaluated the prognostic significance of miR-939 and
SLC34A2 protein expression levels in the GC patients who
underwent surgery followed by chemotherapy. GC patients
with high levels of miR-939 showed better overall survival
Table 1 Correlation between the expression of miR-939 and
therapy response in GC patients (N = 110)
miR-939 expression level
All cases Low expression High expression P value
Therapy response
CR + PR 57 15 42
NC + PD 53 41 12 P < 0.001
CR complete response, PR partial response, NC no change, PD
progressive disease
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(OS) rates and lower tumor recurrence rates than those
with low miR-939 (Fig. 6a, b); whereas GC patients with
high levels of SLC34A2 showed poorer OS rates and
higher tumor recurrence rates than those with low
SLC34A2 (Fig. 6c, d). According to univariate analysis,
miR-939, SLC34A2 level, and TNM stage were significantly
Fig. 2 miR-939 increases cellular sensitivity to 5-Fu in vitro and in vivo. a concentration-dependent growth inhibition in response to 5-Fu in miR-
939-overexpressing, miR-939-silenced, and control GC cells. b quantification of the colony formation efficiency in miR-939-overexpressing, miR-
939-silenced, and control GC cells treated with 5-Fu chemotherapy. c miR-939 sensitizes GC cells to 5-Fu-induced apoptosis. miR-939-
overexpressing and vector control cells treated with indicated dose of 5-Fu for 24 h. Cell apoptotic death events were monitored by Annexin V/PI
staining and flow cytometry assays. d after treatment, cleaved caspase 3 and PARP levels were determined by western blot, and GAPDH was used
as a normalized control. The quantitative values under the bands were the relative ratios cleaved PARP, cleaved caspase-3 to GAPDH from
densitometric analysis. e the same amount (3x106) of miR-939-overexpressing and control GC cells were injected subcutaneously into the
flanks of nude mice. Starting on day 7, the mice were given 5-Fu or DMSO intraperitoneally. f, g and h the tumor volumes (f) and mice
weight (h) were monitored on day 7 and then every 2 days, as indicated, and the xenografts were excised and weighed on day 25 (g).
*P < 0.05, ** P < 0.01
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Fig. 3 (See legend on next page.)
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associated with OS and time to recurrence (TTR) in pa-
tients with GC (Table 2), while multivariate analysis con-
firmed miR-939, SLC34A2 level, and TNM stage as
independent prognostic indicators for both OS and TTR
(Table 2).
Next, we divided patients into four groups based on
miR-939 and SLC34A2 expression levels. GC patients
with high miR-939 and low SLC34A2 had the best OS,
lowest TTR, and best prognosis. In contrast, those with
low miR-939 and high SLC34A2 had the poorest
(See figure on previous page.)
Fig. 3 miR-939 inhibits gastric cancer metastasis in vitro and in vivo. a the wound healing rate in miR-939-transfected cells was significantly inhibited,
while accelerated in miR-939-silenced cells. b the number of migrated cell was decreased in miR-939-overexpressing, while increased in miR-939-
silenced GC cells, as assessed by transwell migration assay. c the number of invaded cell was decreased in miR-939-overexpressing, while increased in
miR-939-silenced GC cells, as assessed by Matrigel invasion assay. d miR-939 inhibits tumor metastasis in vivo. Left panel: hematoxylin and eosin (H&E)
staining was performed on serial sections of metastatic tumors (M) and normal (N) lung. Arrows: lesions of lung. The Ki-67 IHC staining was performed
on tumor metastases. Right panel: the number of nodules was qualified on lungs of SCID mice (n = 6 per group) 4 weeks after tail vein injection of
SGC-7901-scramble (left bars) and SGC7901-miR-939 cells (right bars)
Fig. 4 SLC34A2 is the direct target of miR-939. a predicted miR-939 target sequence in 3'UTR of SLC34A2 (SLC34A2-3′UTR) and mutant containing
three altered nucleotides in the seed sequence of miR-939 (miR-939-mut). b luciferase assay of pGL3-SLC34A2-3′-UTR reporters cotransfected with
increasing amounts (10, 20, and 50 nM) of miR-939 mimic and mutant oligonucleotides in GC cell lines, or with increasing amounts (20, 50, and
100 nM) of miR-939 inhibitor oligonucleotides in GC cell line. c real-time RT-PCR analysis showed that overexpression of miR-939 significantly
suppressed SLC34A2 mRNA expression level of SLC34A2 of GC cells, while inhibition of miR-939 led to a noticeable increase in SLC34A2 mRNA
expression level of GC cell. d western blot analysis demonstrated that miR-939 tranfection decreased SLC34A2 protein level of GC cells, while
anti-miR-939 dramatically increased SLC34A2 protein in GC cell. e high SLC34A2 IHC staining was observed in one GC sample with low miR-939
expression (upper panel); one GC sample with high miR-939 expression showed weak GNA13 IHC staining (lower panel). f the expression of
SLC34A2 was inversely correlated with the expression of miR-939 in 112 GC samples. * P < 0.05, **P <0.001
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Fig. 5 (See legend on next page.)
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prognosis with the lowest OS and highest probability of
tumor recurrence (P < 0.001; Fig. 6e, f ). The combin-
ation of miR-939 and SLC34A2 was an independent
prognostic indicator for OS and TTR (P < 0.001, Table 2).
This combination gave even better prognostic power
than miR-939 or SLC34A2 alone.
Discussion
In this study, we found that miR-939 was indeed down-
regulated in GC tissues. Importantly, we reported, for
the first time, that levels of miR-939 were inversely cor-
related with local relapse, distant metastasis and che-
moresistance in GC patients. In addition, a series of in
vitro and in vivo experiments demonstrated that miR-
939 diminishes GC cell chemoresistance and metastatic
ability by targeting SLC34A2 expression, with conse-
quent inhibition of the Raf-MEK-ERK signaling pathway.
Based on the fact that miRNAs are involved in the ini-
tiation and progression of a variety of cancer types, the
therapeutic potential value of miRNAs in cancer has
been identified. A few in vivo and preclinical studies
have reported modulating miRNA expression for cancer
treatment [17–19]. In general, the therapeutic modula-
tion of miRNAs is achieved by inhibiting oncogenic
miRNAs, or by reconstituting tumor suppressor miR-
NAs [20, 21]. To our knowledge, the relationship be-
tween miR-939 expression and clinical implication in
human cancers has not been analyzed previously. Here,
we reported that miR-939 could repress tumor metasta-
sis and increase the sensitivity of tumor cells to chemo-
therapies in GC. Our results indicated, for the first time,
that the combination of miR-939 and 5-Fu was more ef-
ficient in killing GC cells in vitro and in vivo than using
miR-939 or 5-Fu alone. Besides, we provide comprehen-
sive evidence at cellular levels and in the animal models
that miR-939 may be beneficial for GC patients with
high risks of tumor recurrence and metastasis. Thus, the
examination of miR-939 expression could be applied as
an effective additional tool to optimize clinical decisions,
enabling clinicians to identify those high-risk GC pa-
tients with increased risk of tumor recurrence and/or
metastasis. Based on these findings, modulating miR-939
expression in GC appears to be an encouraging
prototype therapeutic agent for cancer therapy, which
might generate suppressing effect on GC chemotherapy
resistance and distance metastasis. In general, these data
suggested that miR-939 has a pivotal function in GC
pathogenesis, with possible use as a biomarker and inter-
vention point for new therapeutic strategies.
Interestingly, while little is known about the role of
miR-939 in human cancers, miR-939 is among a unique
set of downregulated miRNAs in GC. On the other
hand, however, Ying reported upregulation of miR-939
in human ovarian cancer, which promoted cancer cell
proliferation [22]. By conducting the current study, we
provide compelling biologic as well as clinical evidence
that miR-939 plays a tumor suppressive role in human
GC. These seemingly contradictory findings suggested a
dual role of miR-939 as both a tumor-promoting and
-suppressive miRNA, underscoring the need to define
the specific role of a miRNA in a certain type of cancer.
As miRNAs can play multiple roles by targeting different
genes, it is possible that a single miRNA could function
as both a tumor-promoting or -suppressive miRNA in
different tumor types depending on the genes and/or
pathways they affect [23–25]. Herein, it remains import-
ant to thoroughly understand the molecular mechanisms
mediating the differential biologic effects and targets of
miR-939 in GC and other cancer types. This also under-
scored the need to define the differential biologic effects
and targets of miR-939 in GC and other cancer types.
As described above, miRNAs can play multiple roles by
targeting different genes. In this study, we identified
SLC34A2 as miR-939 target genes. The SLC34A2 gene, lo-
cated on chromosome 4p15.2, is a member of the solute
carrier gene family, which mediate the transport of inor-
ganic phosphate into epithelial cells via sodium ion co-
transport [26, 27]. Recently, function analyses of SLC34A2
in tumorigenesis have yielded contradictory results in dif-
ferent cancer models. Elevated expression of SLC34A2 has
been observed in thyroid cancer and breast cancer [28, 29],
but a significantly decreased expression has been reported
in non-small cell lung carcinomas tissues [29, 30]. How-
ever, the expression pattern and biological role of
SLC34A2 in GC has never been reported. Our data indi-
cate that the restoration of SLC34A2 blocked the miR-939
(See figure on previous page.)
Fig. 5 Alteration of SLC34A2 levels influences the in vitro effects of miR-939 in GC cells. a protein levels of overexpressed SLC34A2 lacking 3'UTR
in miR-939-overexpressing GC cells, as assessed by western blot. b and c MTT analysis (b) and colony formation assay (c) indicated that restoration
of SLC34A2 in miR-939-overexpressing GC cells recovered cellular proliferation and tumorigenicity ability. d Annexin V/PI staining assays showed
that restoration of SLC34A2 in miR-939-overexpressing GC cells decreased 5-Fu-induced apoptosis. e the migratory capacity of miR-939-
overexpressing GC cells was enhanced after transfected with full-length SLC34A2, as assessed by a wound-healing assay. f overexpression of
SLC34A2 in miR-939-transfected cells increased the number of invaded cell, as assessed by a Matrigel invasion assay. g in GC cells with miR-939
overexpression, the expression levels of p-ERK (lane 2) were significantly decreased compared with the control (lane 1). Restoration of SLC34A2
abrogated the decreased expression of p-ERK induced by miR-939 in GC cells (lane 3). Western blot analysis demonstrated that ERK inhibitor
LY294002 (LY) could effectively decrease expressions of p-ERK induced by SLC34A2 (lane 4). h western blot analyses show that the expression of
C-Raf and p-MEK was decreased in miR-939-transfected cells, while increased after SLC34A2 overexpressed
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overexpression-induced inhibition of cancer growth, cell
proliferation, metastasis, and the induction of apoptosis.
In addition, our clinical data show that expression of
SLC34A2 is inversely correlated with miR-939 expression,
and that patients with high expression of SLC34A2 have a
decreased survival rate. Theses data, combined together,
implied a potential oncogenic role of SLC34A2 in GC
tumor development and progression.
The Ras/MEK/ERK pathway is a central signaling
component that plays vital role in the initiation and
regulation of various cellular processes, including prolif-
eration, differentiation, apoptosis and migration [31, 32].
In mitogen-stimulated cells, MEK1/2 activation is dir-
ectly regulated by MAPKs, including Raf-1 kinase, which
phosphorylates 2 serine residues (S218, S222) in the acti-
vation loop of MEK, and thus in turn activates ERK1/2
Fig. 6 The prognostic significance of miR-939 and SLC34A2 for 112 GC patients assessed by Kaplan-Meier analyses. a and b patients with higher
miR-939 had (a) better overall survival (OS) and (b) lower possibility for tumor recurrence. c and d patients with higher SLC34A2 levels in GC tissues
had (c) poorer OS and (d) higher probability of tumor recurrence. e and f patients in subgroup I had the (e) longest OS and (f) lowest possibility of
tumor recurrence among the four subgroups, which were divided according to combinations of miR-939 and SLC34A2, i.e., I, high miR-939/low
SLC34A2; II, high miR-939/high SLC34A2; III, low miR-939/low SLC34A2; IV, low miR-939/high SLC34A2. For each cohort, different subgroups
were plotted according to the cut-off values of miR-939 and SLC34A2, which were defined as the median of the cohort
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[33–35]. Numerous reports have shown the aberrant ac-
tivation of Raf/MEK/ERK pathway in variety of human
cancers [36, 37]. Recent studies also demonstrated aber-
rant regulation of this pathway was associated with can-
cer chemoresistance [14, 15]. In the present study, we
observed that miR-939 overerxpression in GC cells sig-
nificantly decreased MEK1/2 phosphorylation and Raf-1
level, while restoration of SLC34A2 rescued these ef-
fects. Taken together, these findings demonstrated that
SLC34A2 is an integral mediator of miR-939 function in
GC cells via MEK-ERK MAPK pathway inhibition,
which is known to be dysregulated in many cancers.
However, the mechanism by which miR-939-SLC34A2
activates the MAPK signaling pathway is under investi-
gation in our laboratory currently.
Conclusion
In summary, we provide comprehensive evidence of the
inhibitory effect of miR-939 on GC metastasis, and sug-
gest a critical role of miR-939 in enhancing GC cell’s
sensitivities to 5-Fu based chemotherapy. Our findings
strongly suggest that miR-939 could be used for the de-
velopment of novel combinatorial therapy strategies
aimed at overcoming chemo-resistance and compromis-
ing metastasis in GC.
Table 2 Univariate and multivariate analysis of factors associated with overall survival and time to recurrence in GC patients
Overall Survival Time To Recurrence
Clinical Variables HR (95% CI) P value HR (95% CI) P value
Univariate analysis
miR-939 (high versus low) 0.122 (0.053–0.281) <0.001 0.228 (0.121–0.429) <0.001
SLC34A2 (high versus low) 4.555 (2.241–9.260) <0.001 4.179 (2.247–7.769) <0.001
Gender (female versus male) 0.559 (0.294–1.060) 0.075 0.791 (0.441–1.420) 0.433
Age (≥60 versus < 60 years) 1.188 (0.614–2.297) 0.609 1.063 (0.588–1.921) 0.839
T status (T4 versus T1 + 2 + 3) 2.242 (1.182–4.254) 0.013 1.837 (1.042–3.239) 0.035
N status (N2 + 3 versus N1 + 2) 6.324 (2.463–16.239) <0.001 4.928 (2.301–10.555) <0.001
Clinical stage (III versus II) 14.407 (3.461–59.972) <0.001 9.070 (3.250–25.313) <0.001
Tumor size (≥5 cm versus < 5 cm) 2.080 (1.097–3.947) 0.025 2.057 (1.164–3.631) 0.013
Tumor grade (G3 versus G1 + 2) 1.371 (0.667–2.828) 0.389 1.354 (0.716–2.560) 0.351
Combination of miR-939 and SLC34A2
II versus I 3.482 (0.778–15.581) 0.103 2.776 (0.971–7.939) 0.057
III versus I 6.822 (1.801–25.842) 0.005 2.971 (1.074–8.219) 0.036
IV versus I 24.212 (7.049–83.161) <0.001 11.118 (4.688–26.368) <0.001
Multivariate analysisa
miR-939 (high versus low) 0.167 (0.070–0.398) <0.001 0.328 (0.168–0.640) 0.001
SLC34A2 (high versus low) 2.287 (1.050–4.981) 0.037 2.517 (1.276–4.965) 0.008
T status (T4 versus T1 + 2 + 3) 1.642 (0.833–3.233) 0.152 1.403 (0.776–2.533) 0.262
N status (N2 + 3 versus N1 + 2) 3.812 (1.426–10.188) 0.008 3.143 (1.418–6.966) 0.005
Tumor size (≥5 cm versus < 5 cm) 1.784 (0.929–3.425) 0.082 1.754 (0.982–3.133) 0.058
Multivariate analysisb
Combination of miR-939 and SLC34A2
II versus I 3.320 (0.734–15.015) 0.119 2.865 (0.980–8.376) 0.055
III versus I 7.988 (2.077–30.727) 0.003 3.444 (1.224–9.689) 0.019
IV versus I 15.959 (4.498–56.619) <0.001 7.970 (3.249-19.546) <0.001
T status (T4 versus T1 + 2 + 3) 1.697 (0.852–3.382) 0.133 1.423 (0.782–2.590) 0.249
N status (N2 + 3 versus N1 + 2) 3.862 (1.443–10.339) 0.007 3.157 (1.424–7.001) 0.005
Tumor size (≥5 cm versus < 5 cm) 1.833 (0.949–3.543) 0.071 1.789 (0.998–3.240) 0.055
Combination of miR-939 and SLC34A2: I, High miR-939 and Low SLC34A2; II High miR-939 and High SLC34A2; III Low miR-939 and Low SLC34A2; IV Low miR-939
and High SLC34A2
Analysis was conducted using univariate or multivariate Cox proportional hazards regression
aMultivariate analysis of miR-939, SLC34A2, T status, N status and Tumor size
bMultivariate analysis of the combination of miR-939 and SLC34A2, T status, N status and Tumor size
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Additional file 1: Table S1. The clinicopathologic characteristics of the
112 GC patients who received surgery followed by adjuvant
chemotherapy in this study. (DOC 40 kb)
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